Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes

靶向 SWELL1 信号传导治疗肥胖引起的 2 型糖尿病

基本信息

  • 批准号:
    10490426
  • 负责人:
  • 金额:
    $ 99.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-17 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract More than 100 million Americans currently have diabetes or pre-diabetes, a condition that can lead to Type 2 diabetes (T2D) within five years, and that vastly increases adverse cardiovascular events. T2D is characterized by both a loss of insulin sensitivity of target tissues (fat, skeletal muscle, liver) and ultimately, impaired insulin secretion from the pancreatic b-cell. We, and others, recently identified a novel ion channel signaling complex, SWELL1/LRRC8a (Leucine-rich repeat containing protein type 8a) that positively regulates insulin-mediated intracellular signaling in adipose, skeletal muscle, and endothelium, insulin secretion from pancreatic β-cells, and systemic glucose homeostasis. We have identified a small molecule modulator, DCPIB (renamed SN- 401), as a tool compound that binds the SWELL1-LRRC8 complex and functions as a molecular chaperone to augment SWELL1 expression and plasma membrane trafficking. In vivo, SN-401 normalizes glucose tolerance by increasing insulin sensitivity and secretion T2D mouse models. SN-401 augments glucose uptake into adipose tissue and myocardium, suppresses hepatic glucose production, and protects against hepatic steatosis and hepatocyte damage. Combining cryo-EM with molecular docking simulations, and functional studies we have validated a structure-activity relationship (SAR) to generate novel SN-401 congeners with in vivo anti-hyperglycemic activity in T2D models (SN-40X). We propose that small molecule SWELL1 modulators may represent a first-in-class therapeutic approach to treat T2D and associated cardiovascular disease by restoring SWELL1 signaling across multiple organ systems that are dysfunctional in T2D. Our overall objective is to develop a lead series of SN-401 congeners (SN-40X) from which to select one lead compound and one back-up to take into humans, with submission of an Investigational New Drug (IND) application to the FDA in Q1 of 2023. AIM 1: SAR-directed SN-40X optimization and characterization in vitro to refine preclinical lead structures. AIM 2: Perform in vivo dose-range finding toxicity studies, pre-clinical SN-40X dose-response and head-to-head efficacy studies against SGLT2i, empagliflozin and GLP1a, liraglutide AIM 3: Manufacture the lead SN-40X compound under cGMP conditions required for all IND-enabling and 24-month stability studies and some Phase I clinical studies.
项目总结/摘要 目前有超过1亿美国人患有糖尿病或糖尿病前期,这种疾病可能导致2型糖尿病 五年内就会出现糖尿病(T2 D),这会大大增加不良心血管事件。T2 D的特点是 由于靶组织(脂肪、骨骼肌、肝脏)的胰岛素敏感性丧失, 胰腺B细胞分泌物。我们和其他人最近发现了一种新的离子通道信号复合物, SWELL 1/LRRC 8a(富含亮氨酸重复序列的蛋白质8a型),正调节胰岛素介导的 脂肪、骨骼肌和内皮中的细胞内信号传导,胰腺β细胞的胰岛素分泌, 和全身葡萄糖稳态。我们已经鉴定了一种小分子调节剂DCPIB(重命名为SN-1)。 401),作为结合SWELL 1-LRRC 8复合物的工具化合物,并作为分子伴侣发挥作用, 增加SWELL 1表达和质膜运输。在体内,SN-401使葡萄糖耐量正常化 通过增加T2 D小鼠模型的胰岛素敏感性和分泌。SN-401增加葡萄糖摄取, 脂肪组织和心肌,抑制肝脏葡萄糖的产生,并保护肝脏免受 脂肪变性和肝细胞损伤。将冷冻EM与分子对接模拟相结合, 我们已经验证了构效关系(SAR),以产生新的SN-401同系物, T2 D模型中的体内抗高血糖活性(SN-40 X)。我们认为小分子SWELL 1 调节剂可能代表了治疗T2 D及其相关疾病的一流治疗方法 通过恢复跨多个器官系统的SWELL 1信号传导, 2型糖尿病的功能障碍我们的总体目标是开发一系列SN-401同系物(SN-40 X), 选择一种先导化合物和一种备用化合物进入人体, 2023年第一季度向FDA提交研究性新药(IND)申请。 目的1:SAR导向的SN-40 X体外优化和表征,以优化临床前电极导线 结构. 目的2:进行体内剂量范围探索毒性研究、临床前SN-40 X剂量反应和 针对SGLT 2 i、恩格列净和GLP 1a、利拉鲁肽的头对头疗效研究 目的3:在所有IND启用所需的cGMP条件下生产SN-40 X先导化合物 以及24个月稳定性研究和一些I期临床研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel J Lerner其他文献

Daniel J Lerner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel J Lerner', 18)}}的其他基金

Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes
靶向 SWELL1 信号传导治疗肥胖引起的 2 型糖尿病
  • 批准号:
    10384448
  • 财政年份:
    2021
  • 资助金额:
    $ 99.09万
  • 项目类别:
Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis
优化 SWELL1 调节剂治疗非酒精性脂肪性肝炎
  • 批准号:
    10461207
  • 财政年份:
    2020
  • 资助金额:
    $ 99.09万
  • 项目类别:
Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis
优化 SWELL1 调节剂治疗非酒精性脂肪性肝炎
  • 批准号:
    10081592
  • 财政年份:
    2020
  • 资助金额:
    $ 99.09万
  • 项目类别:
Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis
优化 SWELL1 调节剂治疗非酒精性脂肪性肝炎
  • 批准号:
    10397716
  • 财政年份:
    2020
  • 资助金额:
    $ 99.09万
  • 项目类别:

相似国自然基金

相似海外基金

Recruitment of brown adipocytes in visceral white adipose tissue by fibroblast growth factor 8b
成纤维细胞生长因子 8b 将棕色脂肪细胞募集到内脏白色脂肪组织中
  • 批准号:
    321208980
  • 财政年份:
    2016
  • 资助金额:
    $ 99.09万
  • 项目类别:
    Research Grants
Enhancing Energy Expending Adipocytes in White Adipose Tissue
增强白色脂肪组织中的能量消耗脂肪细胞
  • 批准号:
    8827438
  • 财政年份:
    2014
  • 资助金额:
    $ 99.09万
  • 项目类别:
Induction of brown-like adipocytes in white adipose tissue by food-derived factors
食物源性因子在白色脂肪组织中诱导棕色样脂肪细胞
  • 批准号:
    26450168
  • 财政年份:
    2014
  • 资助金额:
    $ 99.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
WAT-on-a-chip - Development of a micofluidic, microphysiologic in vitro adipose tissue model for high-throughput drug screening based on hiPSC-derived adipocytes.
WAT-on-a-chip - 开发微流体、微生理体外脂肪组织模型,用于基于 hiPSC 衍生脂肪细胞的高通量药物筛选。
  • 批准号:
    257256526
  • 财政年份:
    2014
  • 资助金额:
    $ 99.09万
  • 项目类别:
    Research Fellowships
Enhancing Energy Expending Adipocytes in White Adipose Tissue
增强白色脂肪组织中的能量消耗脂肪细胞
  • 批准号:
    8828181
  • 财政年份:
    2013
  • 资助金额:
    $ 99.09万
  • 项目类别:
Enhancing Energy Expending Adipocytes in White Adipose Tissue
增强白色脂肪组织中的能量消耗脂肪细胞
  • 批准号:
    8520690
  • 财政年份:
    2013
  • 资助金额:
    $ 99.09万
  • 项目类别:
Enhancing Energy Expending Adipocytes in White Adipose Tissue
增强白色脂肪组织中的能量消耗脂肪细胞
  • 批准号:
    8629741
  • 财政年份:
    2013
  • 资助金额:
    $ 99.09万
  • 项目类别:
Effect of exercise training on formation of brite adipocytes within white adipose tissue
运动训练对白色脂肪组织内脂肪细胞形成的影响
  • 批准号:
    23700778
  • 财政年份:
    2011
  • 资助金额:
    $ 99.09万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Investigation for the mechanisms of the emergence of brown adipocytes in white adipose tissue
白色脂肪组织中棕色脂肪细胞出现机制的研究
  • 批准号:
    21780261
  • 财政年份:
    2009
  • 资助金额:
    $ 99.09万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
LOUISIANA COBRE: P1: INDUCE THERMOGENIC BROWN ADIPOCYTES IN WHITE ADIPOSE TISSUE
路易斯安那 COBRE:P1:在白色脂肪组织中诱导产热棕色脂肪细胞
  • 批准号:
    7610781
  • 财政年份:
    2007
  • 资助金额:
    $ 99.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了